WILLOW BIOSCIENCES INC (WLLW.CA)
CA97111B4047 - Common Stock
WLLW gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 22 industry peers in the Biotechnology industry. WLLW may be in some trouble as it scores bad on both profitability and health. WLLW is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year WLLW has reported negative net income.
WLLW had a negative operating cash flow in the past year.
In the past 5 years WLLW always reported negative net income.
In the past 5 years WLLW always reported negative operating cash flow.
1.2 Ratios
WLLW has a Return On Assets of -243.30%. This is in the lower half of the industry: WLLW underperforms 61.90% of its industry peers.
The Return On Equity of WLLW (-3956.41%) is better than 61.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -243.3% | ||
| ROE | -3956.41% | ||
| ROIC | N/A |
ROA(3y)-98.13%
ROA(5y)-116.25%
ROE(3y)-163.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
WLLW does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
WLLW does not have a ROIC to compare to the WACC, probably because it is not profitable.
WLLW has more shares outstanding than it did 1 year ago.
The number of shares outstanding for WLLW has been increased compared to 5 years ago.
WLLW has a worse debt/assets ratio than last year.
2.2 Solvency
WLLW has an Altman-Z score of -61.70. This is a bad value and indicates that WLLW is not financially healthy and even has some risk of bankruptcy.
WLLW has a Altman-Z score of -61.70. This is in the lower half of the industry: WLLW underperforms 66.67% of its industry peers.
WLLW has a Debt/Equity ratio of 5.24. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 5.24, WLLW perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -61.7 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
A Current Ratio of 0.80 indicates that WLLW may have some problems paying its short term obligations.
The Current ratio of WLLW (0.80) is worse than 61.90% of its industry peers.
A Quick Ratio of 0.76 indicates that WLLW may have some problems paying its short term obligations.
With a Quick ratio value of 0.76, WLLW perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.55% over the past year.
Looking at the last year, WLLW shows a very strong growth in Revenue. The Revenue has grown by 80.44%.
Measured over the past years, WLLW shows a very strong growth in Revenue. The Revenue has been growing by 389.38% on average per year.
EPS 1Y (TTM)53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.85%
Revenue 1Y (TTM)80.44%
Revenue growth 3Y389.38%
Revenue growth 5YN/A
Sales Q2Q%154.18%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
WLLW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
WLLW does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
WILLOW BIOSCIENCES INC
TSX:WLLW (12/24/2024, 7:00:00 PM)
0.06
+0 (+9.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.1%
Inst Owner ChangeN/A
Ins Owners6.76%
Ins Owner ChangeN/A
Market Cap8.65M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.02 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 44.37 | ||
| P/tB | 44.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.06
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.02
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -243.3% | ||
| ROE | -3956.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-98.13%
ROA(5y)-116.25%
ROE(3y)-163.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.64% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | -61.7 |
F-Score3
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)38.32%
Cap/Depr(5y)91.12%
Cap/Sales(3y)499.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.85%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)80.44%
Revenue growth 3Y389.38%
Revenue growth 5YN/A
Sales Q2Q%154.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.98%
OCF growth 3YN/A
OCF growth 5YN/A